Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
Pharmacology, Toxicology and Pharmaceutical Science
1
3%
Other
2
6%
Unknown
15
42%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2025.
All research outputs
#9,953,776
of 29,790,967 outputs
Outputs from Annals of Oncology
#5,230
of 9,281 outputs
Outputs of similar age
#91,125
of 335,856 outputs
Outputs of similar age from Annals of Oncology
#37
of 46 outputs
Altmetric has tracked 29,790,967 research outputs across all sources so far. This one has received more attention than most of these and is in the 65th percentile.
So far Altmetric has tracked 9,281 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,856 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
